Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

被引：0

作者：

Furstenau, Moritz ^{[1
,2
]}

Giza, Adam ^{[1
,2
]}

Fink, Anna-Maria ^{[1
,2
]}

Robrecht, Sandra ^{[1
,2
]}

Weiss, Jonathan ^{[1
,2
]}

Kleinert, Fanni ^{[1
,2
]}

Schneider, Christof ^{[3
]}

Tausch, Eugen ^{[3
]}

Fischer, Kirsten ^{[1
,2
]}

Langerbeins, Petra ^{[4
,5
,6
]}

Al-Sawaf, Othman ^{[1
,2
]}

Schetelig, Johannes ^{[7
]}

Dreger, Peter ^{[8
]}

Boettcher, Sebastian ^{[9
]}

Kreuzer, Karl-Anton ^{[1
,2
]}

Ritgen, Matthias ^{[10
]}

Schilhabel, Anke ^{[11
]}

Brueggemann, Monika ^{[12
]}

Stilgenbauer, Stephan ^{[3
]}

Eichhorst, Barbara F. ^{[6
]}

Hallek, Michael ^{[1
,2
]}

Cramer, Paula ^{[1
,2
]}

机构：

[1] Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Fac Med, Dept Internal Med, Cologne, Germany

[2] Univ Cologne, German CLL Study Grp, Cologne, Germany

[3] Univ Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[4] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[5] Ctr Integrated Oncol Aachen, Cologne, Germany

[6] Univ Cologne, Cologne, Germany

[7] Tech Univ Dresden, Dept Internal Med 1, Univ Hosp Carl Gustav Carus, Dresden, Germany

[8] Univ Klinikum, Heidelberg, Germany

[9] Univ Hosp, Dept Med Hematol Oncol & Palliat Care 3, Rostock, Germany

[10] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[11] Univ Schleswig Holstein, Dept Internal Med 2, Campus Ki, Kiel, Germany

[12] Univ Clin Schleswig Holstein, Clin Internal Med Haematol 2, Oncol, Kiel, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173708

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 25 条

[1] Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
Fuerstenau, Moritz
Giza, Adam
Weiss, Jonathan
Kleinert, Fanni
Robrecht, Sandra
Franzen, Fabian
Stumpf, Janina
Langerbeins, Petra
Al-Sawaf, Othman
Simon, Florian
Fink, Anna-Maria
Schneider, Christof
Tausch, Eugen
Schetelig, Johannes
Dreger, Peter
Boettcher, Sebastian
Fischer, Kirsten
Kreuzer, Karl-Anton
Ritgen, Matthias
Schilhabel, Anke
Brueggemann, Monika
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
Cramer, Paula
BLOOD, 2024, 144 (03) : 272 - 282
[2] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
Cramer, Paula
Fuerstenau, Moritz
Robrecht, Sandra
Giza, Adam
Fink, Anna
Fischer, Kirsten
Langerbeins, Petra
Al-Sawaf, Othman
Tausch, Eugen
Schneider, Christof
Schetelig, Johannes
Dreger, Peter
Boettcher, Sebastian
Kreuzer, Karl-Anton
Schilhabel, Anke
Brueggemann, Monika
Kneba, Michael
Wendtner, Clemens
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
[3] Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial
Cramer, Paula
Furstenau, Moritz
Robrecht, Sandra
Giza, Adam
Zhang, Can
Fink, Anna-Maria
Fischer, Kirsten
Langerbeins, Petra
Al-Sawaf, Othman
Tausch, Eugen
Schneider, Christof
Schetelig, Johannes
Dreger, Peter
Bottcher, Sebastian
Kreuzer, Karl-Anton
Schilhabel, Anke
Ritgen, Matthias
Bruggemann, Monika
Kneba, Michael
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
LANCET HAEMATOLOGY, 2022, 9 (10): : E745 - E755
[4] Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL
Brown, Jennifer R.
O'Brien, Susan
Kingsley, C. Daniel
Eradat, Herbert
Pagel, John M.
Hirata, Jamie
McIver, Tammy
Morariu-Zamfir, Rodica
Kipps, Thomas J.
BLOOD, 2019, 133 (09) : 990 - 992
[5] MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study
Furstenau, Moritz
Giza, Adam
Schneider, Christof
Tausch, Eugen
Robrecht, Sandra
Ritgen, Matthias
Bittenbring, Joerg
Hebart, Holger F.
Schoettker, Bjoern
Illert, Anna Lena
Graeven, Ullrich
Stoltefuss, Andrea
Heinrich, Bernhard
Eckert, Robert
Fink, Anna-Maria
Stumpf, Janina
Simon, Florian
Fischer, Kirsten
Al-Sawaf, Othman
Langerbeins, Petra
Kleinert, Fanni
Weiss, Jonathan
Kreuzer, Karl-Anton
Schilhabel, Anke
Brueggemann, Monika
Eichhorst, Barbara F.
Stilgenbauer, Stephan
Hallek, Michael
Cramer, Paula
BLOOD, 2023, 142
[6] Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL
Brander, Danielle M.
Seymour, John F.
Kipps, Thomas J.
Ma, Shuo
Anderson, Mary Ann
Choi, Michael Y.
Humphrey, Kathryn
Al Masud, Abdullah
Nandam, Ruby
Jacobson, Amanda
Roberts, Andrew W.
BLOOD, 2019, 134
[7] Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: impact of early MRD kinetics on posttreatment outcomes
Soumerai, Jacob
Dogan, Ahmet
Seshan, Venkatraman
Flaherty, Kelsey
Carter, Jason
Hochberg, Ephraim
Barnes, Jeffrey
Abramson, Jeremy
Hamilton, Audrey
Noy, Ariela
Owens, Colette
Palomba, M. Lia
Kumar, Anita
Roeker, Lindsey
Thompson, Meghan
Takvorian, Ronald
Epstein-Peterson, Zachary
Geyer, Mark
Ramos-Amador, Walter
Mahajan, Neena
Martignetti, Rosalba
Plummer, Sean
Mi, Joanna
Lynch, Julia
McGree, Brianne
Sherburne, Maryanne
Patterson, Emily
Slupe, Natalie
Chabowska, Maria
Labarre, Alyssa
Choma, Morgan
McCambridge, Grace
Kelly, Hailey
Devlin, Mary
Puccio, Madeline
Garcia, Rayna
Grieve, Clare
Cohen, Aileen
Biondo, Juliana
Jacob, Allison
Abdel-Wahab, Omar
Zelenetz, Andrew
LEUKEMIA & LYMPHOMA, 2023, 64 : S103 - S104
[8] LONG-TERM FOLLOW-UP OF A PHASE IB TRIAL OF IDELALISIB IN COMBINATION WITH CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CLL INCLUDING PATIENTS WITH DEL17P/TP53 MUTATION
Barrientos, J.
Coutre, S.
De Vos, S.
Flinn, I.
Wagner-Johnston, N.
Schreeder, M.
Sharman, J.
Boyd, T.
Rai, K.
Leonard, J.
Sorensen, B.
Viggiano, A.
Jahn, T.
Furman, R.
HAEMATOLOGICA, 2015, 100 : 52 - 53
[9] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Popat, Rakesh
Nooka, Ajay
van de donk, Niels
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas
Rosinol, Laura
Mateos Manteca, Maria-Victoria
Bahlis, Nizar J.
Garfall, Alfred
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S80 - S80
[10] Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma
Garfall, Alfred L.
Nooka, Ajay K.
van de Donk, Niels W. C. J.
Moreau, Philippe
Bhutani, Manisha
Oriol, Albert
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar J.
Popat, Rakesh
Besemer, Britta
Martinez-Lopez, Joaquin
Krishnan, Amrita Y.
Delforge, Michel
Huang, Lin
Vishwamitra, Deeksha
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 →